Description: Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Home Page: www.zailaboratory.com
ZLAB Technical Analysis
Jinchuang Plaza
Shanghai,
201210
China
Phone:
86 21 6163 2588
Officers
| Name | Title |
|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO |
| Mr. Ki Chul Cho | Chief Financial Officer |
| Mr. Frazor Titus Edmondson III | Chief Legal Officer & Corp. Sec. |
| Dr. Harald Reinhart M.D. | Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases |
| Mr. Joshua L. Smiley | Chief Operating Officer |
| Dr. Peter Huang Ph.D. | Chief Scientific Officer |
| Ms. Ann E. Beasley J.D. | Chief Compliance Officer |
| Dr. Ning Xu M.D. | Exec. VP & Head of Clinical Operations |
| Dr. Jonathan J. Wang M.B.A., MBA, Ph.D. | Chief Bus. Officer |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of R&D |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1058 |
| Price-to-Sales TTM: | 17.1288 |
| IPO Date: | 2017-09-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 1951 |